Atrium Therapeutics Secures $15 Million Milestone Payment from Bristol Myers Squibb for Cardiovascular Drug Development

Atrium Therapeutics Secures Milestone Payment from Bristol Myers Squibb

San Diego, CA - Atrium Therapeutics, Inc. (Nasdaq: RNA), a pioneering biopharmaceutical company focusing on innovative RNA therapeutics for heart conditions, recently announced that it has secured a $15 million milestone payment from Bristol Myers Squibb (NYSE: BMY). This payment marks a significant achievement in their ongoing collaboration centered on addressing various cardiovascular conditions.

The milestone payment from Bristol Myers Squibb is a result of successful advancements in developing a lead compound aimed at treating a currently undisclosed cardiology indication. Kathleen Gallagher, the President and CEO of Atrium Therapeutics, emphasized the company's commitment to tackling serious heart diseases, including rare genetic cardiomyopathies. She stated, "Advancing our partnership with Bristol Myers Squibb illustrates the flexibility and power of our RNA delivery platform and propels us forward in our mission to deliver effective therapies to patients in need."

Atrium's collaboration with Bristol Myers Squibb is grounded in a comprehensive global licensing agreement that focuses on discovering and developing RNA-based therapies for various cardiovascular indications. The agreement outlines that Atrium could potentially earn up to approximately $1.35 billion in research and development milestones, a further $825 million related to commercial milestones, and royalties that could reach up to low double-digits on net sales. Bristol Myers Squibb is set to cover all future clinical development and commercialization expenses arising from the partnership.

Atrium Therapeutics is making significant strides in the field of heart disease therapy through its innovative RNA delivery methods. With the recent clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for ATR 1072, aimed at treating PRKAG2 syndrome, Atrium is strategically advancing its first precision cardiology initiative into clinical trials. The company’s proprietary technology developed alongside Avidity Biosciences, Inc. uniquely combines the targeted power of monoclonal antibodies with the precision of oligonucleotides. This innovative approach facilitates the focused delivery of small interfering RNA (siRNA) directly to cardiac tissue, a breakthrough method that promises to improve outcomes in genetically driven cardiac diseases.

The current pipeline also includes ATR 1086, targeting PLN (phospholamban) cardiomyopathy. Alongside these promising candidates, Atrium is investing in ongoing research to uncover further leads in treating rare cardiomyopathies.

The success of Atrium’s collaborations reiterates its position as a leader in RNA-based therapeutic advancements aimed at fulfilling significant unmet medical needs within cardiology. As their partnership with Bristol Myers Squibb continues to evolve, patients and families coping with rare and severe heart diseases can look forward to innovative treatment options on the horizon.

For investors, stakeholders, and interested parties, staying updated on Atrium Therapeutics’ progress is crucial. The company actively shares their developments, investor presentations, and other essential information through their official website and LinkedIn pages, encouraging a transparent and informed dialogue within the medical and investment communities. With the increasing focus on biotechnology as a means to enhance patient care, Atrium Therapeutics exemplifies the future of heart disease treatment, driven by technology and innovation.

Conclusion
Atrium Therapeutics’ receipt of this $15 million milestone payment from Bristol Myers Squibb not only marks a financial achievement but also underscores the collaborative effort in developing viable therapies for cardiovascular diseases. It highlights an exciting chapter in the evolution of RNA therapeutics, showcasing the potential for advancements in the treatment of significant health challenges.